Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy

Bone Marrow Transplantation

Volumn 29, Issue 12, 2002, Pages 949-956

  Wu, T ^a,b   Sozen, H ^a   Luo, B ^a   Heuss, N ^a   Kalscheuer, H ^a   Lan, P ^a,c   Sutherland, D E R ^a   Hering, B J ^a   Guo, Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bone marrow transplantation; Chimerism; Immunosuppression; Mice

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; BUSULFAN; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; MR 1; T LYMPHOCYTE ANTIBODY;

ALLOTRANSPLANTATION; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; MALE; METHODOLOGY; MOUSE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD TRANSFUSION; BONE MARROW CELL; CLINICAL PROTOCOL; CONTROLLED STUDY; HEMATOPOIETIC TISSUE; HLA MATCHING; IN VITRO STUDY; IRRADIATION; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BONE MARROW TRANSPLANTATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SIROLIMUS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036327705     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703574     Document Type: Article

References (32)

1. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts
2. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance
3. Mixed chimerism as an approach for the induction of transplantation tolerance
4. Mixed chimerism as an approach to transplantation tolerance
5. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
6. Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning
7. Establishment of stable multilineage hematopoietic chimerism and donor-specific tolerance without irradiation
8. Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow
9. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide
10. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmume destruction and allogeneic and xenogeneic graft rejection
11. High-resolution characterization of cytokine-producing alloreactivity in naive and allograft-primed mice
12. Mls - A retrovirus exploits the immune system
13. Genes encoding ligands for deletion of V beta 11 T cells cosegregate with mammary tumour virus genomes
14. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
15. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance
16. Drug-induced tolerance to allografts in mice. IX. Establishment of complete chimerism by allogeneic spleen cell transplantation from donors made tolerant to H-2-identical recipients
17. Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens
18. Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion
19. Costimulation blockade, busulfan, and bone marrow promote titratable marochimerism, induce transplantation tolerance and correct genetic hemoglobinopathies with minimal myelosuppression
20. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immumosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
21. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome
22. Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administered during the graft-versus-host disease process
23. Graft-versus-host disease prevention by rapamycin: Cellular mechanisms
24. Immunopharmacology of rapamycin
25. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin
26. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
27. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response
28. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment
29. Allogeneic chimerism with low-dose irradiation, antigen presentation, and costimulator blockade in H-2 mismatch mice
30. Requirements for the promotion of allogeneic engraftment by anti-CD154 (antiCD40L) monoclonal antibody under nonmyelablative conditions
31. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation
32. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen